These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29067592)

  • 1. Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations.
    Hsu KH; Gupta K; Nayaka H; Donthi A; Kaul S; Chauhan A
    Pharm Res; 2017 Dec; 34(12):2862-2872. PubMed ID: 29067592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation.
    Hsu KH; Chauhan A
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):30-8. PubMed ID: 26459089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells.
    Datta S; Baudouin C; Brignole-Baudouin F; Denoyer A; Cortopassi GA
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2406-2412. PubMed ID: 28444329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro.
    Clouzeau C; Godefroy D; Riancho L; Rostène W; Baudouin C; Brignole-Baudouin F
    Mol Vis; 2012; 18():851-63. PubMed ID: 22529703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium].
    Seino S; Takada Y; Saika S
    Yakugaku Zasshi; 2021; 141(1):35-39. PubMed ID: 33390445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular benzalkonium chloride exposure: problems and solutions.
    Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
    Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Toxicity research status of benzalkonium chloride on ocular surface].
    Huang C; Chen W; Chen Y; Liu Z
    Zhonghua Yan Ke Za Zhi; 2014 Apr; 50(4):303-6. PubMed ID: 24931157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylaxis with use of eye-drops containing benzalkonium chloride preservative.
    Anderson D; Faltay B; Haller NA
    Clin Exp Optom; 2009 Sep; 92(5):444-6. PubMed ID: 19549228
    [No Abstract]   [Full Text] [Related]  

  • 10. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
    Liang H; Baudouin C; Labbe A; Riancho L; Brignole-Baudouin F
    PLoS One; 2012; 7(3):e33913. PubMed ID: 22442734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops.
    Meloni M; Balzaretti S; Ceriotti L
    Regul Toxicol Pharmacol; 2019 Aug; 106():81-89. PubMed ID: 31039384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
    Levrat F; Pisella PJ; Baudouin C
    J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morphological alterations induced by preservatives in eye drops].
    Huber-van der Velden KK; Thieme H; Eichhorn M
    Ophthalmologe; 2012 Nov; 109(11):1077-81. PubMed ID: 23179812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservatives in eyedrops: the good, the bad and the ugly.
    Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
    Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride.
    Wang YQ; Wang X; Liu P
    Asian Pac J Trop Med; 2013 Dec; 6(12):1004-8. PubMed ID: 24144037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic preservatives: focus on polyquaternium-1.
    Rolando M; Crider JY; Kahook MY
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1425-38. PubMed ID: 21905766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.